Literature DB >> 28945214

Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases.

Eman Abdulfatah1, Sharif Sakr, Sumi Thomas, Zaid Al-Wahab, David G Mutch, Sean Dowdy, Sudeshna Bandyopadhyay, Adnan Munkarah, Mohamed Elshaikh, Robert Morris, Rouba Ali-Fehmi.   

Abstract

OBJECTIVES: Clear cell carcinoma (CCC) comprises a rare yet an aggressive subtype, accounting for less than 5% of all uterine carcinomas. Several clinicopathologic features have been predictive of poor prognosis; however, data remain controversial. The aim of this study was to evaluate the clinicopathologic features of a multi-institutional cohort of endometrial CCC in order to identify which, if any, have prognostic significance.
METHODS: Retrospective review of endometrial CCC diagnosed between 1995 and 2012 at 3 institutions was conducted to evaluate clinicopathologic parameters: age, race, tumor size, stage, myometrial invasion (MI), lymphovascular invasion, lymph node and adnexal involvement, adjuvant therapy, and outcomes. Data were analyzed using Fisher exact, Cox regression, and Kaplan-Meier analyses.
RESULTS: Patients' ages ranged from 36 to 90 years (median, 67 years). The median tumor size was 3.6 cm. Inner-half MI was present in 44%, lymphovascular invasion in 34%, adnexal involvement in 16%, and lymph node metastasis in 30% of cases. Fifty-eight percent of the patients presented with early-stage disease. The 5-year overall survival (OS) was 58%. Shorter disease-free interval (DFI) was significantly associated with older age at diagnosis (>70 years), advanced-stage disease, adnexal involvement, and deep MI (P = 0.005, P = 0.001, P = 0.001, and P = 0.003, respectively). Patients who received adjuvant chemotherapy had a significantly worse DFI and 5-year OS (P = 0.001 and P = 0.001, respectively). A significantly shorter 5-year OS was noted with advanced stage (III-IV) and presence of adnexal involvement (P = 0.001 and P = 0.021, respectively). On Cox regression analysis, advanced-stage disease, older age, and adnexal involvement were significant independent predictors of worse DFI (P = 0.001, P = 0.005, and P = 0.019, respectively), whereas inner-half MI was a significant independent predictor of longer DFI (P = 0.004). Adjuvant radiotherapy alone was a significant independent predictor of better 5-year OS (P = 0.012).
CONCLUSIONS: In our series of endometrial CCC, older age at diagnosis, advanced stage, deep MI, and adnexal involvement were independent poor prognostic factors. Adjuvant radiotherapy had a significant positive impact on 5-year OS.

Entities:  

Mesh:

Year:  2017        PMID: 28945214      PMCID: PMC6152831          DOI: 10.1097/IGC.0000000000001050

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  27 in total

Review 1.  Interleukin 6 and haemostasis.

Authors:  R Kerr; D Stirling; C A Ludlam
Journal:  Br J Haematol       Date:  2001-10       Impact factor: 6.998

Review 2.  Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy.

Authors:  R S Smith; D S Kapp; Q Chen; N N Teng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-10-01       Impact factor: 7.038

Review 3.  Clear cell carcinoma of the endometrium: a biological and clinical enigma.

Authors:  Angiolo Gadducci; Stefania Cosio; Nicoletta Spirito; Luca Cionini
Journal:  Anticancer Res       Date:  2010-04       Impact factor: 2.480

4.  Revised FIGO staging for carcinoma of the cervix.

Authors:  Sergio Pecorelli; Lucia Zigliani; Franco Odicino
Journal:  Int J Gynaecol Obstet       Date:  2009-04-01       Impact factor: 3.561

5.  The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.

Authors:  F D Cirisano; S J Robboy; R K Dodge; R C Bentley; H R Krigman; I S Synan; J T Soper; D L Clarke-Pearson
Journal:  Gynecol Oncol       Date:  2000-04       Impact factor: 5.482

6.  Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases.

Authors:  V M Abeler; K E Kjørstad
Journal:  Gynecol Oncol       Date:  1991-03       Impact factor: 5.482

7.  Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.

Authors:  Oluwole Fadare; Wenxin Zheng; Marta A Crispens; Howard W Iii Jones; Dineo Khabele; Katja Gwin; Sharon X Liang; Khaled Mohammed; Mohamed M Desouki; Vinita Parkash; Jonathan L Hecht
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

Review 8.  Prognostic parameters of endometrial carcinoma.

Authors:  Jaime Prat
Journal:  Hum Pathol       Date:  2004-06       Impact factor: 3.466

Review 9.  Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review.

Authors:  Alexander B Olawaiye; David M Boruta
Journal:  Gynecol Oncol       Date:  2009-02-28       Impact factor: 5.482

10.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.

Authors:  C A Hamilton; M K Cheung; K Osann; L Chen; N N Teng; T A Longacre; M A Powell; M R Hendrickson; D S Kapp; J K Chan
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

View more
  7 in total

1.  Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.

Authors:  Shannon D Armbruster; Rebecca Previs; Pamela T Soliman; Shannon N Westin; Bryan Fellman; Anuja Jhingran; Nicole D Fleming
Journal:  Gynecol Oncol       Date:  2019-06-18       Impact factor: 5.482

2.  Uterine clear cell carcinoma risk in White versus non-White US subpopulations: does race matter?

Authors:  Stephanie Chow; Deanna Wong; Cheng I Liao; Amandeep Mann; Chunqiao Tian; Kathleen M Darcy; John K Chan
Journal:  J Gynecol Oncol       Date:  2020-11       Impact factor: 4.401

3.  Clear Cell Carcinoma of the Endometrium in a Patient Presenting with Postmenopausal Bleeding but Negative Endometrial Biopsy.

Authors:  Swechchha Silwal; Sumeet Kumar Yadav; Benedict Amalraj; Mohamed Mandeel; Geetha Krishnamoorthy
Journal:  Case Rep Oncol       Date:  2021-12-13

4.  Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in 27 Cases.

Authors:  Zhiyang Zhang; Penglian Gao; Zhengqi Bao; Linggong Zeng; Junyi Yao; Damin Chai; Tian Li
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

5.  Prognostic factors in clear cell carcinoma of endometrium: analysis of 55 cases.

Authors:  Vera Loizzi; Ettore Cicinelli; Achiropita Lepera; Francesco Legge; Massimiliano Memmola; Giulia Chiarello; Francesca Arezzo; Vittoria Del Vecchio; Leonardo Resta; Gennaro Cormio
Journal:  Acta Biomed       Date:  2022-01-19

6.  Systematic Lymphadenectomy and Oncological Outcomes of Women With Apparent Early-Stage Clear Cell Carcinoma of the Endometrium: A Multi-Institutional Cohort Study.

Authors:  Yong Tian; Lin Ran; Yi Liu; Yu Xu; Juan Shen; Gong-Sheng Mi; Feng-Mei Ke
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

7.  Napsin-A Expression, a Reliable Immunohistochemical Marker for Diagnosis of Ovarian and Endometrial Clear Cell Carcinomas.

Authors:  Fatemeh Nili; Mansoureh Tavakoli; Narges Izadi Mood; Hana Saffar; Soheila Sarmadi
Journal:  Iran J Pathol       Date:  2020-02-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.